PHOTO
The Ministry of Health and Prevention, MoHAP, announced that it has withdrawn one batch of the API Sinocort Nasal Spray used for the treatment of asthma and blocked airways. The decision was made after having reviewed the study reports of the approved specifications of the drug and that the analysis showed that the batch doesn't conform to those specifications.
The ministry accordingly issued a circular to directors of medical districts, public and private hospitals, physicians, pharmacists, assistant pharmacists, and directors of government and private pharmacies to withdraw one batch of this generic drug manufactured by Amman Jordan Pharmaceutical Industries with batch number ME051.
This comes as part of the Ministry’s efforts to strengthen quality and health safety as per the international standards.
Instructions to drug suppliers, healthcare practitioners, and pharmacists
His Excellency Dr. Amin Hussein Al Amiri, the Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, Chairman of the Supreme National Committee for Pharmacovigilance, explained that the circular is requesting the drug supplier to withdraw the non-conforming batch from the public and private sector and is asking healthcare practitioners not to prescribe it, as well as pharmacists to stop selling the said batch and returning it to the drug supplier.
He urged community members to report any adverse effects of the batch, if used, via the following email: ph@moh.gov.ae or through the E-system on MoHAP’s website, or the smart app ‘UAE RADAR’, noting that all drug-related circulars are available on the ministry’s website.
He further urged the individuals to dispose of the said batch, if any, and to consult with their attending physicians to prescribe conforming batches of the medicine, emphasizing MoHAP’s commitment to protecting the health and safety of the society and that the Pharmacovigilance Committee is constantly communicating with international drug authorities, as well as local and international pharmaceutical companies to keep up to date with the updates of drug-related safety warnings.
-Ends-
© Press Release 2020
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
